• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

乳腺癌筛查的潜在净危害:福雷斯特报告的更新建模。

Possible net harms of breast cancer screening: updated modelling of Forrest report.

机构信息

Faculty of Medicine, Wessex Institute, University of Southampton, Southampton SO16 7PX, UK.

出版信息

BMJ. 2011 Dec 8;343:d7627. doi: 10.1136/bmj.d7627.

DOI:10.1136/bmj.d7627
PMID:22155336
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3234304/
Abstract

OBJECTIVE

To assess the claim in a Cochrane review that mammographic breast cancer screening could be doing more harm than good by updating the analysis in the Forrest report, which led to screening in the United Kingdom.

DESIGN

Development of a life table model, which replicated Forrest's results before updating and extending them with data from relevant systematic reviews, trials, and other models based on purposive literature searches.

PARTICIPANTS

Women aged 50 and over invited for breast cancer screening.

MAIN OUTCOME MEASURES

Quality adjusted life years (QALYs), combining life years gained from screening with losses of quality of life from false positive diagnoses and surgery.

RESULTS

Inclusion of the effects of harms reduced the updated estimate of net cumulative QALYs gained after 20 years from 3301 to 1536 or by more than half. The best estimates from the Cochrane review generated negative QALYs for the first seven years of screening, 70 QALYs after 10 years, and 834 QALYs after 20 years. Sensitivity analysis showed these results were robust to a range of assumptions, particularly up to 10 years. It also indicated the importance of the level and duration of harms from surgery.

CONCLUSIONS

This analysis supports the claim that the introduction of breast cancer screening might have caused net harm for up to 10 years after the start of screening.

摘要

目的

通过更新福雷斯特报告中的分析来评估 Cochrane 综述中提出的乳房 X 线筛查可能弊大于利的说法,该报告导致了英国开始进行筛查。

设计

开发寿命表模型,该模型复制了福雷斯特的结果,然后使用来自相关系统评价、试验和其他基于有针对性文献搜索的模型的数据对其进行更新和扩展。

参与者

邀请 50 岁及以上的女性进行乳腺癌筛查。

主要观察指标

质量调整生命年(QALYs),将筛查获得的生命年与假阳性诊断和手术导致的生活质量损失结合起来。

结果

纳入危害影响后,更新后的 20 年后净累积 QALYs 获益估计值从 3301 减少到 1536,降幅超过一半。 Cochrane 综述的最佳估计值在前 7 年的筛查中产生了负 QALYs,10 年后为 70 QALYs,20 年后为 834 QALYs。敏感性分析表明,这些结果对各种假设具有稳健性,尤其是在前 10 年。它还表明手术危害的程度和持续时间的重要性。

结论

这项分析支持了这样一种说法,即乳腺癌筛查的引入可能在筛查开始后长达 10 年内造成净危害。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3c4/4788322/ba899f0c852a/rafj795690.f3_default.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3c4/4788322/71252bef29f7/rafj795690.f1_default.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3c4/4788322/af023d1cf98c/rafj795690.f2_default.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3c4/4788322/ba899f0c852a/rafj795690.f3_default.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3c4/4788322/71252bef29f7/rafj795690.f1_default.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3c4/4788322/af023d1cf98c/rafj795690.f2_default.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3c4/4788322/ba899f0c852a/rafj795690.f3_default.jpg

相似文献

1
Possible net harms of breast cancer screening: updated modelling of Forrest report.乳腺癌筛查的潜在净危害:福雷斯特报告的更新建模。
BMJ. 2011 Dec 8;343:d7627. doi: 10.1136/bmj.d7627.
2
Retrospective cost-effectiveness analysis of screening mammography.乳腺钼靶筛查的回顾性成本效益分析。
J Natl Cancer Inst. 2006 Jun 7;98(11):774-82. doi: 10.1093/jnci/djj210.
3
Quality-of-life effects of screening mammography in Norway.挪威筛查性乳房 X 光摄影对生活质量的影响。
Int J Cancer. 2020 Apr 15;146(8):2104-2112. doi: 10.1002/ijc.32539. Epub 2019 Sep 6.
4
Benefits and Harms of Breast Cancer Screening: A Systematic Review.乳腺癌筛查的获益与危害:系统评价。
JAMA. 2015 Oct 20;314(15):1615-34. doi: 10.1001/jama.2015.13183.
5
Cost effectiveness of the NHS breast screening programme: life table model.英国国家医疗服务体系乳腺癌筛查计划的成本效益:寿命表模型。
BMJ. 2013 May 9;346:f2618. doi: 10.1136/bmj.f2618.
6
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
7
Swiss Medical Board Mammography screening predictions for Switzerland: importance of time-periods.瑞士医学委员会 瑞士乳腺钼靶筛查预测:时间段的重要性
J Med Screen. 2015 Dec;22(4):201-6. doi: 10.1177/0969141315586639. Epub 2015 May 27.
8
Cost-effectiveness of Population-Wide Genomic Screening for Hereditary Breast and Ovarian Cancer in the United States.美国人群遗传性乳腺癌和卵巢癌基因筛查的成本效益分析。
JAMA Netw Open. 2020 Oct 1;3(10):e2022874. doi: 10.1001/jamanetworkopen.2020.22874.
9
Tailoring Breast Cancer Screening Intervals by Breast Density and Risk for Women Aged 50 Years or Older: Collaborative Modeling of Screening Outcomes.根据乳腺密度和风险调整50岁及以上女性的乳腺癌筛查间隔:筛查结果的协作建模
Ann Intern Med. 2016 Nov 15;165(10):700-712. doi: 10.7326/M16-0476. Epub 2016 Aug 23.
10
Benefits, harms, and cost-effectiveness of supplemental ultrasonography screening for women with dense breasts.对乳腺致密的女性进行补充超声筛查的益处、危害及成本效益
Ann Intern Med. 2015 Feb 3;162(3):157-66. doi: 10.7326/M14-0692.

引用本文的文献

1
No association between breast pain and breast cancer: a prospective cohort study of 10 830 symptomatic women presenting to a breast cancer diagnostic clinic.乳房疼痛与乳腺癌之间无关联:一项纳入 10830 例因乳房症状就诊于乳腺癌诊断门诊的女性的前瞻性队列研究。
Br J Gen Pract. 2022 Mar 31;72(717):e234-e243. doi: 10.3399/BJGP.2021.0475. Print 2022 Apr.
2
Overview in Breast Cancer Screening in Lebanon.黎巴嫩乳腺癌筛查概述。
Cancer Control. 2021 Jan-Dec;28:10732748211039443. doi: 10.1177/10732748211039443.
3
Cost-effectiveness of risk-based breast cancer screening programme, China.

本文引用的文献

1
Likelihood that a woman with screen-detected breast cancer has had her "life saved" by that screening.通过筛查检测出患有乳腺癌的女性其“生命得以挽救”的可能性。
Arch Intern Med. 2011 Dec 12;171(22):2043-6. doi: 10.1001/archinternmed.2011.476. Epub 2011 Oct 24.
2
Is mammographic screening justifiable considering its substantial overdiagnosis rate and minor effect on mortality?考虑到乳腺钼靶筛查存在大量过度诊断率且对死亡率影响较小,这种筛查是否合理?
Radiology. 2011 Sep;260(3):621-7. doi: 10.1148/radiol.11110210.
3
A randomised controlled trial of post-operative radiotherapy following breast-conserving surgery in a minimum-risk population. Quality of life at 5 years in the PRIME trial.
基于风险的乳腺癌筛查计划的成本效益,中国。
Bull World Health Organ. 2018 Aug 1;96(8):568-577. doi: 10.2471/BLT.18.207944. Epub 2018 Jun 28.
4
Saliva samples as a source of DNA for high throughput genotyping: an acceptable and sufficient means in improvement of risk estimation throughout mammographic diagnostics.唾液样本作为高通量基因分型的 DNA 来源:在提高乳腺 X 线照相诊断中的风险评估方面,是一种可接受且充分的手段。
Eur J Med Res. 2018 Apr 27;23(1):20. doi: 10.1186/s40001-018-0318-9.
5
Optoacoustic response of gold nanorods in soft phantoms using high-power diode laser assemblies at 870 and 905 nm.使用870纳米和905纳米高功率二极管激光组件对软质仿体中的金纳米棒进行光声响应研究。
Biomed Opt Express. 2017 Feb 7;8(3):1430-1440. doi: 10.1364/BOE.8.001430. eCollection 2017 Mar 1.
6
Ultrasound positive predictive values by BI-RADS categories 3-5 for solid masses: An independent reader study.BI-RADS 类别 3-5 实性肿块的超声阳性预测值:独立读者研究。
Eur Radiol. 2017 Oct;27(10):4307-4315. doi: 10.1007/s00330-017-4835-7. Epub 2017 Apr 10.
7
Economic analysis of the breast cancer screening program used by the UK NHS: should the program be maintained?英国国民医疗服务体系(NHS)所采用的乳腺癌筛查项目的经济分析:该项目是否应继续实施?
Breast Cancer (Dove Med Press). 2017 Mar 24;9:217-225. doi: 10.2147/BCTT.S123558. eCollection 2017.
8
Breast Cancer Screening for Women at Average Risk: 2015 Guideline Update From the American Cancer Society.平均风险女性的乳腺癌筛查:美国癌症协会2015年指南更新
JAMA. 2015 Oct 20;314(15):1599-614. doi: 10.1001/jama.2015.12783.
9
Mammography screening is harmful and should be abandoned.乳腺钼靶筛查有害,应予以摒弃。
J R Soc Med. 2015 Sep;108(9):341-5. doi: 10.1177/0141076815602452.
10
Quantification of population benefit in evaluation of biomarkers: practical implications for disease detection and prevention.评估生物标志物中的人群获益量化:对疾病检测和预防的实际意义。
BMC Med Inform Decis Mak. 2014 Mar 6;14:15. doi: 10.1186/1472-6947-14-15.
保乳手术后辅助放疗在低危人群中的随机对照试验。PRIME 试验 5 年时的生活质量。
Health Technol Assess. 2011 Mar;15(12):i-xi, 1-57. doi: 10.3310/hta15120.
4
Advanced breast cancer incidence following population-based mammographic screening.基于人群的乳腺 X 线筛查后的晚期乳腺癌发病情况。
Ann Oncol. 2011 Aug;22(8):1726-35. doi: 10.1093/annonc/mdq633. Epub 2011 Jan 20.
5
Health-state utility values in breast cancer.乳腺癌患者的健康状态效用值。
Expert Rev Pharmacoecon Outcomes Res. 2010 Oct;10(5):553-66. doi: 10.1586/erp.10.65.
6
Absolute numbers of lives saved and overdiagnosis in breast cancer screening, from a randomized trial and from the Breast Screening Programme in England.从一项随机试验和英国乳腺癌筛查计划中得出的乳腺癌筛查中挽救的生命绝对数量和过度诊断。
J Med Screen. 2010;17(1):25-30. doi: 10.1258/jms.2009.009094.
7
The background review for the USPSTF recommendation on screening for breast cancer.美国预防服务工作组(USPSTF)关于乳腺癌筛查建议的背景审查。
Ann Intern Med. 2010 Apr 20;152(8):538; author reply 538-9. doi: 10.7326/0003-4819-152-8-201004200-00198. Epub 2010 Feb 15.
8
Multicentre randomised controlled trial examining the cost-effectiveness of contrast-enhanced high field magnetic resonance imaging in women with primary breast cancer scheduled for wide local excision (COMICE).多中心随机对照试验研究计划行广泛局部切除术的原发性乳腺癌女性中增强高磁场磁共振成像的成本效益(COMICE)。
Health Technol Assess. 2010 Jan;14(1):1-182. doi: 10.3310/hta14010.
9
Screening for breast cancer: an update for the U.S. Preventive Services Task Force.乳腺癌筛查:美国预防服务工作组的更新。
Ann Intern Med. 2009 Nov 17;151(10):727-37, W237-42. doi: 10.7326/0003-4819-151-10-200911170-00009.
10
A rapid-response economic evaluation of the UK NHS Cancer Reform Strategy breast cancer screening program extension via a plausible bounds approach.基于似然边界法对英国国民保健署(NHS)癌症改革战略乳腺癌筛查项目扩展的快速反应经济评估。
Value Health. 2010 Mar-Apr;13(2):215-21. doi: 10.1111/j.1524-4733.2009.00667.x. Epub 2009 Oct 29.